Re: Farmas USA
CLDX
Al bastardo le gusta de cara al ASCO:
Celldex Therapeutics (CLDX - Get Report) is one of the most interesting "ASCO plays" for presentation of final results from the Rintega "ReACT" study in patients with recurrent (previously treated) brain cancer. I covered the details about the Rintega data and the possibility of an earlier-than-expected FDA approval filing in a February Mailbag.